CASC3 and age-related macular degeneration: Furthermore, in addition to the targeting effectof AMD, it is also plausible that AMD-induced disruption of MM cellretention in the bone niche sensitized the MM cells to BTZ therapy,as previously reported.50 Indeed, suchstudies demonstrated the additive advantage of combining AMD withBTZ when both drugs are administered as free drugs.